Novo Nordisk introduced Ozempic to investors in India.

Ozempic Launched in India

The innovations in the pharmaceutical sector continue to attract attention. Novo Nordisk (NVO) has announced the launch of Ozempic, a once-weekly injectable medication effective in diabetes treatment, in India. The weekly price for the 0.25 mg dose has been set at $24.35.

The Rise of Ozempic

Approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes in 2017, Ozempic has gained worldwide popularity due to its appetite-suppressing effects. In addition to being widely used by individuals looking to lose weight, it has also emerged as an important solution in the fight against obesity.

Market Potential in India

India holds significant market potential for such medications, particularly as rates of overweight and obesity continue to rise. With the launch of Ozempic, the growth in healthy living and diabetes treatment presents an attractive opportunity for investors. Most analysts predict that the global market created by such medications could reach $150 billion annually in the next decade.

New Solution: Wegovy

Additionally, Novo Nordisk’s other drug, Wegovy, which contains the same active ingredient, has been approved as a direct treatment option for weight loss. By entering the Indian market, these two drugs provide solutions for those seeking answers to growing health issues.